• 1
    Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Progress of chronic hepatitis C: results of a large, prospective cohort study. HEPATOLOGY 1998; 28: 16871695.
  • 2
    Dusheiko GM. The natural course of chronic hepatitis C: implications for clinical practice. J Viral Hepatol 1998; 5(Suppl 1): 912.
  • 3
    Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930938.
  • 4
    Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 12281233.
  • 5
    Akuta N, Chayama K, Suzuki F, Someya T, Kobayashi M, Tsubota A, et al. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 allele. J Med Virol 2001; 64: 109116.
  • 6
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Group. N Engl J Med 1989; 321: 15011506.
  • 7
    Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 15061510.
  • 8
    Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372380.
  • 9
    Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 8390.
  • 10
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403410.
  • 11
    Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 2005; 40: 688696.
  • 12
    Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 2005; 3(10 Suppl 2 ): S132S135.
  • 13
    Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 10651067.
  • 14
    Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, et al. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 1993; 8: 150156.
  • 15
    Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. An amino-acid substitution detection system for the HCV-1b core region. J Virol Method 2007; 141: 16.
  • 16
    Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 1990; 87: 95249528.
  • 17
    Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 15131520.
  • 18
    Moriishi K, Okabayashi T, Nakai K, Moriya K, Koike K, Murata S, et al. Proteasome activator PA28γ-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol 2003; 77: 1023710249.
  • 19
    Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, et al. Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A 2007; 104: 16611666.
  • 20
    Ogata S, Florese RH, Nagano-Fujii M, Hidajat R, Deng L, Ku Y, et al. Identification of hepatitis C virus subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. J Clin Microbiol 2003; 41: 28352841.
  • 21
    Giménez-Barcons M, Franco S, Suárez Y, Forns X, AmpurdanéAges S, Puig-Basagoiti F, et al. High amino acid variability within the NS5A of hepatitis C virus is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. HEPATOLOGY 2001; 34: 158167.
  • 22
    Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999; 30: 653659.
  • 23
    Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. HEPATOLOGY 1999; 29: 11241130.
  • 24
    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk of hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174181.
  • 25
    Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, et al. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 370376.